EP3873601A4 - METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES - Google Patents
METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES Download PDFInfo
- Publication number
- EP3873601A4 EP3873601A4 EP20804811.6A EP20804811A EP3873601A4 EP 3873601 A4 EP3873601 A4 EP 3873601A4 EP 20804811 A EP20804811 A EP 20804811A EP 3873601 A4 EP3873601 A4 EP 3873601A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diabetes
- prevention
- compositions
- methods
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847466P | 2019-05-14 | 2019-05-14 | |
| PCT/US2020/032891 WO2020232247A1 (en) | 2019-05-14 | 2020-05-14 | Methods and compositions for preventing type 1 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3873601A1 EP3873601A1 (en) | 2021-09-08 |
| EP3873601A4 true EP3873601A4 (en) | 2022-03-23 |
Family
ID=75926572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20804811.6A Pending EP3873601A4 (en) | 2019-05-14 | 2020-05-14 | METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3873601A4 (en) |
| CN (2) | CN112839707A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007147090A2 (en) * | 2006-06-14 | 2007-12-21 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| WO2015073833A1 (en) * | 2013-11-15 | 2015-05-21 | Pharmacyclics, Inc. | Methods for delaying or preventing the onset of type 1 diabetes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904586A1 (en) * | 2013-03-08 | 2014-09-12 | The Curators Of The University Of Missouri | Methods and compositions for the treatment and/or prevention of type 1 diabetes |
| ES3038990T3 (en) * | 2017-09-08 | 2025-10-16 | Diamyd Medical Ab | Genotype stratification in diabetes treatment and prevention |
-
2020
- 2020-05-14 EP EP20804811.6A patent/EP3873601A4/en active Pending
- 2020-05-14 CN CN202080005325.2A patent/CN112839707A/en active Pending
- 2020-05-14 CN CN202411340301.9A patent/CN119236066A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007147090A2 (en) * | 2006-06-14 | 2007-12-21 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| WO2015073833A1 (en) * | 2013-11-15 | 2015-05-21 | Pharmacyclics, Inc. | Methods for delaying or preventing the onset of type 1 diabetes |
Non-Patent Citations (8)
| Title |
|---|
| ANONYMOUS: "Anti-CD3 Prevention ANTI-CD3 MAB (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS (Protocol TN-10)", TYPE 1 DIABETES TRIALNET, 25 June 2014 (2014-06-25), XP055889308, Retrieved from the Internet <URL:https://clinicaltrials.gov/ProvidedDocs/61/NCT01030861/Prot_000.pdf> [retrieved on 20220209] * |
| JANELLE A NOBLE ET AL: "Genetics of the HLA Region in the Prediction of Type 1 Diabetes", CURRENT DIABETES REPORTS, CURRENT SCIENCE INC, NEW YORK, vol. 11, no. 6, 13 September 2011 (2011-09-13), pages 533 - 542, XP019971883, ISSN: 1539-0829, DOI: 10.1007/S11892-011-0223-X * |
| KEVAN C. HEROLD ET AL: "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 7, 15 August 2019 (2019-08-15), US, pages 603 - 613, XP055760445, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1902226 * |
| LONG ET AL.: "Partial exhaustion of CD 8 T cells and clinical response to teplizumab in new-onset type 1 diabetes", SCIENCE IMMUNOLOGY, vol. 1, no. 5, 18 November 2016 (2016-11-18), XP055760444 * |
| MANNERING S I ET AL: "The case for an autoimmune aetiology of type 1 diabetes", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 183, no. 1, 21 October 2015 (2015-10-21), pages 8 - 15, XP071082897, ISSN: 0009-9104, DOI: 10.1111/CEI.12699 * |
| See also references of WO2020232247A1 * |
| WHERRETT DIANE K. ET AL: "Prevention of Type 1 Diabetes", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA., vol. 38, no. 4, 1 December 2009 (2009-12-01), PHILADELPHIA, pages 777 - 790, XP055889301, ISSN: 0889-8529, DOI: 10.1016/j.ecl.2009.08.006 * |
| WU YAN-LING ET AL: "Risk Factors and Primary Prevention Trials for Type 1 Diabetes", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 9, no. 7, 18 July 2013 (2013-07-18), pages 666 - 679, XP055889302, ISSN: 1449-2288, DOI: 10.7150/ijbs.6610 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112839707A (en) | 2021-05-25 |
| EP3873601A1 (en) | 2021-09-08 |
| CN119236066A (en) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3874030A4 (en) | COMPOSITIONS AND METHODS FOR ENGINEERING T LYMPHOCYTES | |
| MA55082A (en) | COMPOSITIONS, METHODS, AND KITS FOR THE ADMINISTRATION OF POLYRIBONUCLEOTIDES | |
| EP3894343A4 (en) | METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF CARBON DIOXIDE | |
| MA53445A (en) | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS | |
| EP3924478A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GLYCOGENOSIS TYPE 1A | |
| EP3612215A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY INFLAMMATION | |
| EP3635100A4 (en) | COMPOSITIONS AND METHODS FOR EXPRESSING OTOFERLINE | |
| MA53391A (en) | COMPOSITIONS FOR AGRICULTURE AND RELATED PROCESSES | |
| EP3793562A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | |
| EP3893655A4 (en) | METHODS FOR THE PREPARATION OF A VEGETABLE PROTEIN COMPOSITION | |
| EP4009778A4 (en) | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ECTOMYCORHIZAL MYCELIUMS AND METHODS OF USE THEREOF | |
| MA45688A (en) | COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS | |
| EP3803403A4 (en) | IMAGING COMPOSITIONS AND METHODS | |
| EP3801534A4 (en) | COMPOSITIONS AND METHODS FOR INCREASE TETRAHYDROBIOPTERINE PLASMA EXPOSURE | |
| EP3735457A4 (en) | COMPOSITIONS AND METHODS FOR PRODUCING MEGACARYOCYTES | |
| EP3810109A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | |
| EP3990920A4 (en) | METHODS AND COMPOSITIONS FOR PROXIMITY LIGATURE | |
| MA52961A (en) | COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF INFLAMMATION | |
| EP3980774A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING AUTOANTIBODIES | |
| EP3788070A4 (en) | HEMOGLOBIN PRODUCTION COMPOSITIONS AND METHODS | |
| EP4058035A4 (en) | IMMUNOTHERAPY COMPOSITIONS AND METHODS | |
| EP3638277A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITION OF BETA-SECRETASE | |
| MA49651A (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSION DEFECTS | |
| EP3803416A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING TRAUMATIC BRAIN INJURY | |
| MA55531A (en) | METHODS FOR THE TREATMENT OF BETA-THALASSEMIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210603 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220217 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 5/50 20060101ALI20220215BHEP Ipc: A61K 38/28 20060101ALI20220215BHEP Ipc: A61P 5/48 20060101AFI20220215BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20220304 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |